04-20-2026Price:

The Frontier

Your signal. Your price.

SCIENCE

Fraud unravels Alzheimer's research dogma

Monday, April 20, 2026 · from 1 podcast
1 SOURCEFreakonomics Radio
  • A 2006 fake image in Nature set Alzheimer’s research back decades, funneling $2.7B into failed drugs.
  • NIH official Eliezer Masliah oversaw research with 132 flawed papers, now under investigation.
  • Whistleblower Matthew Shrag says the field must abandon amyloid obsession for vascular health.

A single manipulated Western blot image in a 2006 Nature paper didn’t just deceive - it derailed an entire field. That image, crafted by Sylvain Lesné, purported to show a specific amyloid oligomer as the toxic agent in Alzheimer’s. It became the foundation of the amyloid cascade hypothesis, the dominant theory for over 30 years. But forensic analysis by neuroscientist Matthew Shrag revealed the bands were copy-pasted and retouched. The paper was retracted - after two decades of clinical trials built on its falsehood.

"The data was structurally altered to support the hypothesis. It wasn’t just sloppy - it was manufactured."

- Matthew Shrag, Freakonomics Radio

The damage extends far beyond one paper. Investigative journalist Charles Pillar uncovered over 100 publications by NIH neuroscientist Eliezer Masliah containing similar image irregularities - many from the same era, many funded by the agency’s $2.7 billion Alzheimer’s budget. Masliah, who oversaw grant allocations, left his post without public comment. The NIH has not initiated a formal review of the affected studies.

The amyloid hypothesis didn’t just dominate - it suffocated. Drug development fixated on clearing plaques, leading to FDA approvals like Aduhelm, which removed amyloid but failed to stop cognitive decline. Billions were spent while alternative theories - like Shrag’s focus on cerebral waste clearance and vascular health - were starved of funding and dismissed as fringe.

"The field was hijacked. Careers, grants, and prestige all depended on one story. When that story is built on fraud, the whole structure collapses."

- Charles Pillar, Freakonomics Radio

Institutions protected reputations, not truth. The University of Minnesota delayed investigating Lesné for years, allowing continued federal funding. Whistleblowers faced isolation. Even Shrag found fraud in his own mentor’s work, calling it 'exaggeration' to clarify results - resulting in multiple retractions. The culture isn’t just permissive of fraud - it rewards it.

Science can’t self-correct when the gatekeepers are compromised. The FDA’s revolving door with pharma, NIH’s silence on its own leaders, and universities’ loyalty to prestige over rigor have all enabled decades of misdirection. The cost isn’t just financial - it’s every year stolen from patients waiting for real treatments.

BiologyMental HealthRegulation
NatureFDANIH

Source Intelligence

- Deep dive into what was said in the episodes

Freakonomics Radio
Freakonomics Radio

671. Why Has There Been So Little Progress on Alzheimer’s Disease? • Apr 17

  • Charles Piller argues the amyloid hypothesis has dominated Alzheimer's research since 1990, directing tens of billions in funding toward drugs that remove beta-amyloid plaques but fail to arrest cognitive decline.
  • Matthew Schrag states anti-amyloid antibody drugs like aducanumab are dangerous, causing brain swelling and bleeding, and offer only imperceptibly subtle cognitive benefits. He notes aducanumab was withdrawn for being ineffective and dangerous.
  • Piller and Schrag's investigation found apparent image manipulation in 132 of 800 papers by influential NIH neuroscientist Eliezer Maslia, tracing problems back 30 years. The NIH made no comment when Maslia left his post.
  • A seminal 2006 Nature paper by Sylvain Lesné and Karen Ash, which proposed a specific amyloid oligomer as the toxic cause of Alzheimer's, was retracted after Schrag and Piller found its Western blot images were severely manipulated to support the hypothesis.
  • Schrag discovered his mentor, Othman Ghribi, had manipulated images in their joint research, describing it as 'exaggeration' to make results clearer. Multiple papers were retracted, and Ghribi stated he took full responsibility as lab director.
  • Piller cites a Public Citizen report concluding regulatory capture has infiltrated the FDA, noting 11 of 16 FDA examiners for Alzheimer's drug approvals left to work for the companies they regulated.
  • The NIH spends about $4 billion annually on Alzheimer's and dementia research, second only to cancer spending and up from $1 billion a decade ago.
  • Schrag reformulates Alzheimer's as a disease of failed waste clearance in the brain, arguing a broader approach targeting blood vessel health and aggressive blood pressure control shows more promise than singular amyloid focus.
  • Casava Sciences paid a $40 million SEC settlement for misleading investors about its drug simufilam, which failed clinical trials. Scientist Hoau-Yan Wang was indicted for data fabrication but charges were later dropped.
Also from this episode: (1)

Health (1)

  • Alzheimer's affects over 7 million people in the U.S., with higher prevalence and earlier onset linked to pollution exposure, lower educational attainment, and economic inequality.
HealthBrainBiology

Related Stories